Perdagangan Monopar Therapeutics Inc. - MNPR CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | - | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.024874% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | 0.002651% | ||||||||
Waktu biaya inap | 21:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | USD | ||||||||
Margin | 20% | ||||||||
Bursa efek | United States of America | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
Key Stats
Prev. Close* | N/A |
Open* | N/A |
1-Year Change* | N/A |
Day's Range* | N/A |
52 wk Range | 1.35-4.88 |
Average Volume (10 days) | 91.87K |
Average Volume (3 months) | 732.34K |
Market Cap | 19.53M |
P/E Ratio | -100.00K |
Shares Outstanding | 13.19M |
Revenue | N/A |
EPS | -0.83 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | May 10, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|
Monopar Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, April 3, 2023 | ||
Time (UTC) 17:00 | Country US
| Event Monopar Therapeutics Inc at Jefferies Radiopharma Innovation Summit Monopar Therapeutics Inc at Jefferies Radiopharma Innovation SummitForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | |||
Total Operating Expense | 10.5369 | 9.12725 | 6.50888 | 4.32376 | 3.33115 |
Selling/General/Admin. Expenses, Total | 2.94528 | 2.63404 | 2.44368 | 2.35524 | 1.55669 |
Research & Development | 7.5916 | 6.49321 | 4.0652 | 1.96852 | 1.77445 |
Operating Income | -10.5369 | -9.12725 | -6.50888 | -4.32376 | -3.33115 |
Interest Income (Expense), Net Non-Operating | 0.02124 | 0.02402 | 0.0819 | 0.09889 | 0.10322 |
Net Income Before Taxes | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Net Income After Taxes | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Net Income Before Extra. Items | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Net Income | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Income Available to Common Excl. Extra. Items | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Income Available to Common Incl. Extra. Items | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Diluted Net Income | -10.5156 | -9.10322 | -6.30457 | -4.22487 | -3.22793 |
Diluted Weighted Average Shares | 12.7182 | 12.4722 | 10.9583 | 10.421 | 10.421 |
Diluted EPS Excluding Extraordinary Items | -0.82682 | -0.72988 | -0.57533 | -0.40542 | -0.30975 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -0.82682 | -0.72988 | -0.57533 | -0.40542 | -0.30975 |
Other, Net | 0 | 0.1224 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 2.909 | 2.40735 | 2.76335 | 2.45719 | 2.68112 |
Selling/General/Admin. Expenses, Total | 0.80874 | 0.67512 | 0.68488 | 0.77925 | 0.69844 |
Research & Development | 2.10297 | 1.73223 | 2.07847 | 1.67793 | 1.98268 |
Operating Income | -2.909 | -2.40735 | -2.76335 | -2.45719 | -2.68112 |
Interest Income (Expense), Net Non-Operating | 0.01266 | 0.0077 | 0.00042 | 0.00046 | 0.00053 |
Net Income Before Taxes | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Net Income After Taxes | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Net Income Before Extra. Items | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Net Income | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Income Available to Common Excl. Extra. Items | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Income Available to Common Incl. Extra. Items | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Diluted Net Income | -2.89634 | -2.39965 | -2.76293 | -2.45672 | -2.68059 |
Diluted Weighted Average Shares | 12.8795 | 12.7547 | 12.6324 | 12.6044 | 12.5919 |
Diluted EPS Excluding Extraordinary Items | -0.22488 | -0.18814 | -0.21872 | -0.19491 | -0.21288 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Diluted Normalized EPS | -0.22488 | -0.18814 | -0.21872 | -0.19491 | -0.21288 |
Other Operating Expenses, Total | -0.00271 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 20.5216 | 16.7998 | 13.2296 | 7.25222 | 9.13124 |
Cash and Short Term Investments | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
Cash & Equivalents | 20.3039 | 16.7371 | 13.2139 | 6.89277 | 8.98189 |
Other Current Assets, Total | 0.21775 | 0.06269 | 0.01571 | 0.35945 | 0.14934 |
Total Assets | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
Other Long Term Assets, Total | 0 | 0.06886 | 0.12238 | 0.06573 | 0.80003 |
Total Current Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Payable/Accrued | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.58054 | 1.17667 | 0.72417 | 0.39955 | 0.31187 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 18.9411 | 15.692 | 12.6279 | 6.9184 | 9.6194 |
Preferred Stock - Non Redeemable, Net | |||||
Common Stock | 0.0126 | 0.01145 | 0.01059 | 0.00929 | 0.00929 |
Additional Paid-In Capital | 60.22 | 47.8736 | 38.5088 | 28.5672 | 28.0379 |
Other Equity, Total | -0.00316 | -0.00787 | -0.01097 | -0.0024 | -18.4278 |
Total Liabilities & Shareholders’ Equity | 20.5216 | 16.8687 | 13.352 | 7.31796 | 9.93127 |
Total Common Shares Outstanding | 12.5981 | 11.4535 | 10.6215 | 10.421 | 10.421 |
Retained Earnings (Accumulated Deficit) | -41.2884 | -32.1852 | -25.8806 | -21.6557 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 18.0127 | 20.5216 | 22.4484 | 24.3884 | 25.8377 |
Cash and Short Term Investments | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
Cash & Equivalents | 17.819 | 20.3039 | 22.3416 | 24.2929 | 25.7231 |
Other Current Assets, Total | 0.19364 | 0.21775 | 0.1068 | 0.09556 | 0.11457 |
Total Assets | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
Other Long Term Assets, Total | 0 | 0.06886 | 0.06886 | 0.06886 | |
Total Current Liabilities | 1.07412 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Payable/Accrued | 1.04815 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.09946 | 1.58054 | 1.23994 | 1.10364 | 0.80627 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 16.9669 | 18.9411 | 21.2773 | 23.3536 | 25.1003 |
Common Stock | 0.01262 | 0.0126 | 0.01259 | 0.01258 | 0.01257 |
Additional Paid-In Capital | 60.7031 | 60.22 | 59.8776 | 59.4955 | 59.162 |
Retained Earnings (Accumulated Deficit) | -43.7451 | -41.2884 | -38.6078 | -36.1493 | -34.0692 |
Other Equity, Total | -0.00374 | -0.00316 | -0.00515 | -0.00516 | -0.0051 |
Total Liabilities & Shareholders’ Equity | 18.0664 | 20.5216 | 22.5172 | 24.4573 | 25.9065 |
Total Common Shares Outstanding | 12.6206 | 12.5981 | 12.5906 | 12.5827 | 12.5699 |
Property/Plant/Equipment, Total - Net | 0.05369 | ||||
Accrued Expenses | 0.02598 | ||||
Other Liabilities, Total | 0.02534 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.10322 | -6.30457 | -4.22487 | -3.22793 | -16.5549 |
Cash From Operating Activities | -7.3174 | -4.66227 | -3.01768 | -2.68049 | -2.62747 |
Non-Cash Items | 1.46805 | 1.19849 | 1.01117 | 0.52933 | 13.8068 |
Changes in Working Capital | 0.31777 | 0.44381 | 0.19602 | 0.01811 | 0.12058 |
Cash From Financing Activities | 10.8795 | 8.18212 | 9.34741 | -0.20627 | 9.53639 |
Financing Cash Flow Items | -0.06325 | -0.11557 | -0.98481 | -0.20627 | 4.83074 |
Issuance (Retirement) of Stock, Net | 10.9428 | 8.17529 | 10.3322 | 0 | 4.70565 |
Net Change in Cash | 3.56676 | 3.52318 | 6.32116 | -2.88915 | 6.90892 |
Foreign Exchange Effects | 0.00462 | 0.00333 | -0.00857 | -0.0024 | |
Cash Taxes Paid | 0 | -0.0111 | |||
Issuance (Retirement) of Debt, Net | 0.1224 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.45672 | -9.10322 | -6.42263 | -3.96419 | -1.88402 |
Cash From Operating Activities | -2.4675 | -7.3174 | -5.2855 | -3.34418 | -1.93806 |
Non-Cash Items | 0.49981 | 1.46805 | 1.11789 | 0.72583 | 0.36823 |
Changes in Working Capital | -0.51059 | 0.31777 | 0.01925 | -0.10582 | -0.42227 |
Cash From Financing Activities | -0.01667 | 10.8795 | 10.8873 | 10.8973 | 10.9213 |
Financing Cash Flow Items | -0.01667 | -0.06325 | -0.05548 | -0.0455 | -0.0215 |
Issuance (Retirement) of Stock, Net | 0 | 10.9428 | 10.9428 | 10.9428 | 10.9428 |
Foreign Exchange Effects | -0.00066 | 0.00462 | 0.00264 | 0.00263 | 0.00277 |
Net Change in Cash | -2.48483 | 3.56676 | 5.60446 | 7.55574 | 8.986 |
Issuance (Retirement) of Debt, Net | 0 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Tacticgem LLC | Corporation | 31.1621 | 4111273 | 0 | 2022-04-15 | LOW |
Gem Pharmaceuticals LLC | Corporation | 23.1589 | 3055394 | 0 | 2022-04-15 | LOW |
Hendricks (Diane) | Individual Investor | 3.553 | 468750 | 0 | 2022-04-15 | LOW |
Brown Michael J | Individual Investor | 1.711 | 225730 | 2859 | 2022-12-31 | LOW |
Tactic Pharma LLC | Corporation | 1.2633 | 166667 | 0 | 2022-04-15 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.7578 | 99976 | 97 | 2022-12-31 | LOW |
Robinson (Chandler D) | Individual Investor | 0.5816 | 76730 | 4396 | 2023-01-01 | LOW |
Starr (Christopher M) | Individual Investor | 0.4937 | 65130 | 2859 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3175 | 41892 | 2721 | 2022-12-31 | LOW |
Cittadine (Andrew) | Individual Investor | 0.2038 | 26894 | 2656 | 2022-12-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1735 | 22884 | -293 | 2022-12-31 | LOW |
Mazar (Andrew Paul) | Individual Investor | 0.1677 | 22125 | 0 | 2022-04-15 | LOW |
Klausner (Arthur J) | Individual Investor | 0.1571 | 20730 | 2859 | 2022-12-31 | LOW |
Tsuchimoto (Kim R) | Individual Investor | 0.1403 | 18507 | 728 | 2023-01-01 | MED |
Anderson (Raymond William) | Individual Investor | 0.1268 | 16730 | 2859 | 2022-12-31 | MED |
Northern Trust Global Investments | Investment Advisor | 0.1 | 13197 | 0 | 2022-12-31 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.0303 | 4000 | 0 | 2022-12-31 | LOW |
UBS Financial Services, Inc. | Investment Advisor | 0.0239 | 3154 | -2245 | 2022-12-31 | LOW |
Tower Research Capital LLC | Hedge Fund | 0.0215 | 2831 | -300 | 2022-12-31 | HIGH |
Paragon Wealth Strategies, LLC | Investment Advisor | 0.0004 | 58 | 0 | 2022-12-31 | HIGH |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group500K+
Trader
92K+
Klien aktif per bulan
$53M+
Volume investasi per bulan
$30M+
Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Biotechnology & Medical Research (NEC) |
1000 Skokie Blvd Ste 350
WILMETTE
ILLINOIS 60091-1146
US
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com